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Background-—Gut microbiota is emerging as a novel risk factor for atherothrombosis, but the predictive role of gut-derived
lipopolysaccharide (LPS) is unknown. We analyzed (1) the association between LPS and major adverse cardiovascular events
(MACE) in atrial fibrillation (AF) and (2) its relationship with adherence to a Mediterranean diet (Med-diet).
Methods and Results-—This was a prospective single-center study including 912 AF patients treated with vitamin K antagonists
(3716 patient-years). The primary end point was a composite of MACE. Baseline serum LPS, adherence to Med-diet (n=704), and
urinary excretion of 11-dehydro-thromboxane B2 (TxB2, n=852) were investigated. Mean age was 73.5 years; 42.9% were women.
A total of 187 MACE (5.0% per year) occurred: 54, 59, and 74 in the first, second, and third tertile of LPS, respectively (log-rank test
P=0.004). Log-LPS (hazard ratio 1.194, P=0.009), age (hazard ratio 1.083, P<0.001), and previous cerebrovascular (hazard ratio
1.634, P=0.004) and cardiac events (hazard ratio 1.822, P<0.001) were predictors of MACE. In the whole cohort, AF (versus sinus
rhythm) (b 0.087, P=0.014) and low-density lipoprotein cholesterol (b 0.069, P=0.049) were associated with circulating LPS.
Furthermore, Med-diet score (b !0.137, P<0.001) was predictive of log-LPS, with fruits (b !0.083, P=0.030) and legumes (b
!0.120, P=0.002) negatively associated with log-LPS levels. Log-LPS and log-TxB2 were highly correlated (r=0.598, P<0.001). Log-
LPS (b 0.574, P<0.001) and Med-diet score (b !0.218, P<0.001) were significantly associated with baseline urinary excretion of
TxB2.
Conclusions-—In this cohort of AF patients, LPS levels were predictive of MACE and negatively affected by high adherence to Med-
diet. LPS may contribute to MACE incidence in AF by increasing platelet activation. ( J Am Heart Assoc. 2017;6:e005784. DOI:
10.1161/JAHA.117.005784.)
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T here is mounting evidence to indicate that gut micro-biota is responsible for systemic inflammation and
contributes to different pathologies such as diabetes mellitus,
obesity, hypertension, and chronic inflammatory gut disease.1
Recent data are also in favor of the hypothesis that gut
microbiota may represent a novel risk factor for atheroscle-
rosis and thrombosis. Experimental and clinical studies
discovered that intestinal microbiota produces molecules
such as trimethylamine N-oxide (TMAO), which may be
implicated in both processes.2,3 TMAO stems from microbial
conversion of dietary nutrients containing choline, phos-
phatidylcholine, and L-carnitine to trimethylamine, which is
absorbed by the intestinal tube and converted to TMAO by a
hepatic flavin monooxygenase 3.4 Studies in animals have
demonstrated that TMAO possesses proatherogenic property,
and clinical studies have demonstrated that circulating levels
of TMAO independently predicted cardiovascular events such
as myocardial infarction and cardiovascular death.5 More
recent studies have also documented that TMAO possesses
prothrombotic effect by activating human platelets via
increased release of Ca2+ from intracellular stores.6
Other products of gut microbiota, such as lipopolysaccha-
ride (LPS), may also be involved in the atherothrombosis
process. LPS is a potentially interesting molecule that, once it
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crosses the gut mucosa and enters into the systemic
circulation, may lead to atherosclerosis, possibly via chronic
inflammation and thrombosis.7 About 100 trillion gut bacte-
ria contribute to an enteric reservoir of >1 g LPS, which
travels in the circulation of healthy subjects in a range of
"10 to 200 pg/mL.8 LPS is translocated to human circu-
lation with chylomicrons and, therefore, increases after a
meal, particularly in the case of a fatty meal, suggesting a
prominent role of diet in modulating circulating LPS.9,10 In
addition, in some clinical settings such as hypertension, LPS
may enter the systemic circulation as a consequence of
increased gut permeability due to an impairment of tight
junctions.11,12 Experimental studies have showed that LPS is
proatherogenic in vivo as its injection in mice and rabbits
accelerates the formation of plaque.13 In humans, a
relationship between LPS levels and carotid atherosclerosis
has been documented,14 and circulating LPS has been found
to be increased in several conditions associated with
atherosclerosis, such as type 2 diabetes mellitus and
obesity.8,15 However, so far, no data regarding LPS and
clinical outcomes have been reported.
Atrial fibrillation (AF) is themost common cardiac arrhythmia
and is complicated by cardiovascular events of thromboembolic
and atherothrombotic origin such as ischemic stroke, periph-
eral embolism, andmyocardial infarction.16 Taking into account
that LPS may play a role not only in the atherosclerotic process
but also in clotting and platelet activation, we tested the
hypothesis that LPS could be associated with cardiovascular
events in AF patients. For this purpose, we performed a
prospective, observational study in AF to assess (1) the
relationship between circulating LPS and cardiovascular out-
comes during a follow-up of about 3 years and (2) the
association between LPS and adherence to Med-diet and
consumption of its components.
Methods
Study Design
This prospective single-center study included patients with
nonvalvular AF who were referred to the center for monitoring
and management of antithrombotic therapies by the Depart-
ment of Internal Medicine and Medical Specialties of Sapien-
za-University of Rome.
All patients were treated with vitamin K antagonists after
appropriate thrombotic risk stratification.17 International
normalized ratio values were maintained in an intended range
between 2.0 to 3.0, and time in therapeutic range was
calculated to assess the quality of anticoagulation.18 Exclu-
sion criteria were prosthetic heart valves or the presence of
any severe valvulopathies, severe cognitive impairment,
chronic infections (human immunodeficiency virus infection,
hepatitis C virus, hepatitis B virus), or autoimmune systemic
disease. Subjects were also excluded from the study if they
had active cancer or liver insufficiency (eg, cirrhosis).
At baseline, each patient provided written informed
consent, the patient’s medical history was recorded, and
cardiovascular risk factors, such as arterial hypertension,19
diabetes mellitus,20 and heart failure21 were defined accord-
ing to international guidelines.
Major Adverse Cardiovascular Events
The primary outcome of the study was a combined end point of
major adverse cardiovascular events (MACE) including fatal/
nonfatal myocardial infarction and ischemic stroke, cardiac
revascularization (stent or coronary artery bypass surgery),
cardiovascular death, and transient ischemic attack. Diagnosis of
myocardial infarction was made according to the definition
proposed by the Joint ESC/ACCF/AHA/WHF Task Force.22
Ischemic stroke was determined on clinical manifestations and
confirmed by radiological findings; a transient ischemic attack
was defined according to the Classification of Cerebrovascular
Diseases III.23 If a patient died within 4 weeks of myocardial
infarction or ischemic stroke, this event was recorded as fatal
myocardial infarction or fatal ischemic stroke, respectively.
Death was classified as vascular unless the central adjudication
committee (see below) confirmed an unequivocal noncardiovas-
cular cause of death. Cardiovascular death included death due to
peripheral artery disease, hemorrhagic stroke, sudden death,
progressive congestive heart failure, and procedure-related
death. Data on MACE were prospectively collected, and only
the first event that occurred during follow-up was used in the
analysis. Details on MACE were registered, and death
Clinical Perspective
What Is New?
• In this observational prospective study we found a signif-
icant association between circulating LPS levels and risk of
MACE in a large cohort of atrial fibrillation patients treated
with vitamin K antagonists; in particular, patients in the
highest tertile of LPS (>100 pg/mL) had the highest risk of
MACE.
• Circulating LPS levels were inversely associated with
adherence to a Mediterranean diet (Med-diet), in particular
with fruit and legume intake.
What Are the Clinical Implications?
• The inverse association between adherence to Med-diet and
circulating LPS suggests the need to explore the effect of an
ad hoc nutritional or pharmacologic interventional study
aimed at lowering LPS in atrial fibrillation patients.
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certificates, hospital discharge letter, or copy of the medical
records of hospitalization and other clinical documentation (ie,
radiology and laboratory data) were also obtained from patients
or, in case of death, from relatives of patients or from a general
practitioner. All patients provided a written informed consent at
baseline. The study protocol was approved by the local ethical
board of Sapienza-University of Rome (n° 1306/2007) and was
conducted according to principles of the Declaration of
Helsinki.24
Laboratory Analysis
At baseline, a lipid profile including total cholesterol (mg/dL),
high-density lipoprotein (mg/dL), and triglycerides (mg/dL)
was obtained. Low-density lipoprotein (mg/dL) cholesterol was
calculated by the validated Friedwald formula, and very low-
density lipoprotein (mg/dL) cholesterol as triglycerides/5.
Serum Lipopolysaccharide
Lipopolysaccharide serum levels were measured using a
commercial ELISA kit (Cusabio, Wuhan, China). Standards of
LPS, purified from Escherichia coli, and blood samples were
plated for 2 hours at room temperature onto a microplate
precoated with the antibody specific for LPS. After incuba-
tion, samples were read at 450 nm. Values were expressed
as picograms per milliliter; intra-assay and interassay
coefficients of variation were 8% and 10%, respectively.
Urinary 11-dehydro-thromboxane B2
The excretion of urinary 11-dehydro-thromboxane B2 (TxB2)
was measured by an enzyme-linked immunosorbent assay
commercial kit (Cayman Chemical, Ann Arbor, MI), as
previously described.25 Data are expressed as nanograms
per milligram creatinine. Intra-assay and interassay coeffi-
cients of variation were 4.0% and 3.6%, respectively.
Adherence to Mediterranean Diet
In a subgroup of AF patients, we investigated the relationship
between adherence to Med-diet and circulating LPS. Adher-
ence to Med-diet was assessed by a validated short
questionnaire, as previously described.26
Table 1. Baseline Characteristics of AF Patients According to the Occurrence of MACE
Overall MACE
P Value(n=912) No (n=728) Yes (n=184)
Age, y 73.5#8.3 72.7#8.4 76.7#7.1 <0.001
Female sex, % 42.9 43.3 41.2 0.620
AF (persistent/permanent AF) vs sinus rhythm, % 53.1 52.0 57.2 0.218
Current smoking, % 9.5 9.5 9.6 0.964
Body mass index, kg/m2 27.5#4.7 27.5#4.9 27.2#3.8 0.315
Arterial hypertension, % 89.7 89.0 92.5 0.096
Previous cardiac events, % 24.8 20.6 41.2 <0.001
Diabetes mellitus, % 20.1 18.3 26.7 0.014
Heart failure, % 16.1 13.5 26.2 <0.001
Previous cerebrovascular events, % 14.5 11.6 25.7 <0.001
Antiplatelet drugs, % 19.7 18.1 26.2 0.017
Statins, % 41.4 41.9 39.6 0.618
Total cholesterol, mg/dL 177.5#39.7 178.2#37.8 174.8#47.0 0.297
HDL cholesterol, mg/dL 47.1#13.8 47.6#13.7 45.2#14.0 0.037
LDL cholesterol, mg/dL 106.5#32.4 106.9#30.9 105.1#37.5 0.528
Triglycerides, mg/dL 118.2#54.0 117.2#52.2 121.8#60.2 0.298
VLDL cholesterol, mg/dL 23.6#10.8 23.4#10.4 24.4#12.0 0.339
LPS, pg/mL 50.0 (15.0-108.0) 50.0 (15.0-103.0) 55.0 (20.0-151.0) 0.021
Urinary 11-dehydro-thromboxane B2 (n=852) 120.0 (70.0-196.5) 115.0 (68.0-184.0) 149.5 (90.0-274.0) <0.001
AF indicates atrial fibrillation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LPS, lipopolysaccharide; MACE, major adverse cardiovascular events; VLDL, very low-density
lipoprotein.
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Statistical Analyses
Categorical variables were reported as counts (percentage),
and Pearson chi-squared test was used to compare proportions.
Continuous variables were expressed as mean#standard
deviation or median and interquartile range, depending on their
distribution, which was assessed by the Kolmogorov-Smirnov
test. Bivariate analysis was performed with Pearson linear
correlation. Appropriate nonparametric tests (Mann-Whitney U
test and Spearman rank correlation test) were employed for all
bivariate analyses with nonnormal variables. Continuous vari-
ables with nonnormal distribution were log-transformed for
multivariate analysis. After dividing the cohort into tertiles
according to LPS values, the cumulative risk for MACE was
estimated using a Kaplan-Meier method. The survival curves
were then formally compared using the log-rank test. Cox
proportional hazards analysis was used to calculate the
adjusted relative hazards of MACE by each clinical variable.
For multivariable analyses, LPS values were log transformed.
Multivariable linear regression analyseswere used to determine
factors associated with serum log-LPS and urinary TxB2 levels.
In a subgroup of 704 AF patients who completed the Med-
diet questionnaire, we evaluated the adherence to Med-diet.
We divided the cohort according to the median value of the
Med-diet score to compare biochemical characteristics of
patients with low (0-5 points) versus high (6-9 points)
adherence to Med-diet. We built 2 separate models of
multivariable linear regression analyses, 1 with Med-diet score
as a continuous variable and another with single foods. All tests
were 2-tailed, and analyses were performed using computer
software packages (SPSS-18.0, IBM, Armonk, NY). Only P
values <0.05 were considered as statistically significant.
Figure. Kaplan-Meier curve estimates of survival free from major adverse cardiovascular
events according to tertiles of lipopolysaccharide (LPS).
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Results
Study Population Characteristics
Of the 998 patients initially included, 37 were excluded
because of missing biological samples, and 49 were lost to
follow-up; thus, 912 AF patients composed the prospective
study cohort. Baseline characteristic of the whole cohort are
described in Table 1. Mean age was 73.5#8.3 years, and
42.9% were women. Most patients were hypertensive (89.7%),
20.1% were diabetic, and 16.1% had heart failure. A previous
cardiac or cerebrovascular event was present in 24.8% and
14.5%, respectively. Median CHA2DS2-VASc score was 4.0
(3.0-4.0) points.
LPS and MACE
Median follow-up was 40.0 (20.5-68.0) months, yielding 3716
patient-years of observation. During follow-up, 187 (5.0% per
year) MACE were registered: 139 cardiac outcomes (3.7% per
year; 41 fatal/nonfatal myocardial infarctions, 20 cardiac
revascularizations, 78 cardiovascular deaths) and 48 cere-
brovascular events (1.3% per year; 41 fatal/nonfatal ischemic
strokes and 7 transient ischemic attacks). Compared with those
without, patients with a MACE were older and had a higher
prevalence of diabetes mellitus, HF, history of ischemic events,
and lower high-density lipoprotein cholesterol (Table 1).
In the whole cohort, median LPS was 50.0 (15.0-108.0)
pg/mL. Median value of LPS was 10.0 (7.0-15.0) pg/mL in
the first tertile, 50.0 (33.0-65.0) in the second, and 145.0
(108.0-180.0) in the third tertile. Survival analysis
demonstrated a significant difference in risk of MACE across
tertiles of LPS, with 54, 59, and 74 MACE in the first, second,
and third tertiles, respectively (log-rank test P=0.004, Figure).
In particular, as compared to the first, we found a nonsignif-
icantly increased risk of MACE in the second tertile of LPS
(hazard ratio 1.304, 95%CI 0.901-1.888, P=0.159), while the
third tertile, conferred the highest risk of MACE (hazard ratio
1.795, 95%CI 1.263-2.552, P=0.001). Multivariable Cox
regression analysis is reported in Table 2; we found that
log-LPS, age, and previous cerebrovascular and cardiac events
were independent predictors of MACE (Table 2). We obtained
similar risks for log-LPS (hazard ratio 1.382, 95%CI 1.115-
1.712, P=0.003) after adjustment for time in therapeutic
range (hazard ratio 0.988, 95%CI 0.977-0.999, P=0.029).
Determinants of LPS
We performed a multivariable linear regression analysis in the
whole cohort to assess factors associated with circulating log-
LPS.We found that AF (versus sinus rhythm) (b0.087, P=0.014)
and low-density lipoprotein cholesterol (b 0.069, P=0.049)
were associated with circulating log-LPS (Table 3, model A).
In 704 of 912 AF patients we assessed the adherence to
Med-diet: median Med-diet score was 5.0 (4.0-6.0). Med-diet
score and log-LPS levels were significantly and inversely
correlated (r=!0.144, P<0.001). A second model of multi-
variable linear regression analysis adjusting for Med-diet
score showed that AF (versus sinus rhythm) and Med-diet
score were predictors of circulating log-LPS, whereas asso-
ciation between low-density lipoprotein cholesterol and log-
LPS was attenuated (Table 3, model B). According to the
median value of Med-diet score, we did not find any difference
regarding lipid profile (Table 4).
Then, we investigated LPS levels according to the intake of
single foods included in the Med-diet questionnaire (Table 5)
and found significantly lower LPS levels in patients with a high
intake of fruit and legumes; a trend was also evident for low
intake of meat (Table 5). The negative association between
log-LPS and intakes of fruit (b !0.083, P=0.030) and legumes
(b !0.120, P=0.002) remained significant at multivariable
linear regression analysis (after adjustment for variables listed
in Table 3, model B).
LPS and Platelet Activation
Median 11-dehydro-TxB2 was 120.0 (70.0-196.5) ng/mg
creatinine (n=852). Patients experiencing a MACE (n=184)
disclosed significantly higher levels of urinary 11-dehydro-
TxB2 compared with those who did not (149.5 [90.0-274.0]
versus 115.0 [68.0-184.0]ng/mg, P<0.001).
Log-LPS and log-TxB2 were highly correlated (r=0.598,
P<0.001); Med-diet and log-TxB2 were inversely correlated
Table 2. Predictors of MACE (Multivariable Cox Proportional
Hazard Analysis)
Hazard Ratio (95%CI) P Value
AF vs sinus rhythm 0.840 (0.620-1.138) 0.260
Log-LPS 1.194 (1.045-1.364) 0.009
Female sex 0.800 (0.589-1.086) 0.153
Age 1.083 (1.060-1.107) <0.001
Arterial hypertension 1.022 (0.583-1.790) 0.940
Diabetes mellitus 1.348 (0.964-1.884) 0.081
Current smoking 1.527 (0.922-2.530) 0.100
Heart failure 1.383 (0.971-1.969) 0.072
Previous cerebrovascular events 1.634 (1.166-2.290) 0.004
Previous cardiac events 1.822 (1.317-2.521) <0.001
Antiplatelet drugs 1.009 (0.723-1.410) 0.957
Statins 1.061 (0.777-1.450) 0.709
Body mass index 1.015 (0.979-1.051) 0.428
Statins have been used instead of lipid profile for the model. AF indicates atrial
fibrillation; LPS, lipopolysaccharide.
DOI: 10.1161/JAHA.117.005784 Journal of the American Heart Association 5
Atrial Fibrillation and Lipopolysaccharides Pastori et al
O
R
IG
IN
A
L
R
E
SE
A
R
C
H
 by guest on November 27, 2017
http://jaha.ahajournals.org/
Downloaded from 
(r=!0.310, P<0.001). A multivariable linear regression anal-
ysis showed that log-LPS (b 0.574, P<0.001) and Med-diet
score (b !0.218, P<0.001) were significantly associated with
urinary excretion of 11-dehydro-TxB2 (after adjustment for
variables listed in Table 3, model B).
Discussion
This is the first prospective study reporting a significant
association between circulating LPS and MACE occurrence in
a large cohort of AF patients. Circulating levels of LPS were
higher in patients with AF compared with those with sinus
rhythm, and were not associated with classical cardiovascular
risk factors. After controlling for Med-diet adherence, we
found an inverse association between LPS and Med-diet
score, in particular with fruit and legume intake.
In the present study, we found a rate of MACE of 5% per
year, which is consistent with other reports.27,28 This is in
accordance with Gallego et al, who found in a cohort of 529
AF patients a rate of thrombotic/cardiovascular events of
5.17% per year in a median follow-up of 28 months28. Similar
findings have been recently reported in a study including 754
Table 3. Multivariable Linear Regression Analysis of Factors Affecting Circulating Log-LPS
Unstandardized
Coefficients
Standardized
Coefficients
P Value
95.0%CI
B SE b Lower Upper
Model A
AF vs sinus rhythm 0.193 0.079 0.087 0.014 0.038 0.347
Female sex !0.067 0.079 !0.030 0.394 !0.223 0.088
Age 0.003 0.005 0.022 0.547 !0.007 0.013
Body mass index 0.002 0.008 0.007 0.857 !0.015 0.018
Arterial hypertension 0.060 0.127 0.017 0.634 !0.188 0.309
Diabetes mellitus 0.084 0.097 0.030 0.389 !0.107 0.275
Current smoking !0.249 0.131 !0.066 0.058 !0.506 0.008
Heart failure 0.077 0.107 0.025 0.475 !0.134 0.287
Previous cerebrovascular events 0.028 0.110 0.009 0.797 !0.187 0.243
Previous cardiac events 0.077 0.096 0.030 0.425 !0.112 0.266
Antiplatelet drugs !0.174 0.100 !0.063 0.082 !0.369 0.022
Triglycerides !0.001 0.001 !0.038 0.274 !0.002 0.001
LDL cholesterol 0.002 0.001 0.069 0.049 0.000 0.005
Model B
AF vs sinus rhythm 0.242 0.085 0.113 0.005 0.075 0.410
Female sex !0.164 0.087 !0.075 0.060 !0.334 0.007
Age 0.006 0.006 0.044 0.299 !0.005 0.017
Body mass index 0.001 0.009 0.003 0.940 !0.017 0.019
Arterial hypertension 0.103 0.145 0.028 0.475 !0.181 0.388
Diabetes mellitus 0.111 0.109 0.041 0.307 !0.102 0.324
Current smoking !0.195 0.144 !0.053 0.177 !0.478 0.088
Heart failure 0.003 0.123 0.001 0.983 !0.239 0.245
Previous cerebrovascular events 0.003 0.127 0.001 0.981 !0.247 0.253
Previous cardiac events !0.014 0.113 !0.005 0.899 !0.237 0.208
Antiplatelet drugs !0.193 0.118 !0.067 0.102 !0.425 0.038
Triglycerides 0.000 0.001 !0.005 0.901 !0.002 0.002
LDL cholesterol 0.002 0.001 0.072 0.067 0.000 0.005
Med-diet score !0.098 0.028 !0.137 <0.001 !0.152 !0.043
Statin use, total, HDL, and VLDL cholesterol were excluded from the model for collinearity. AF indicates atrial fibrillation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SE,
standard error; VLDL, very low-density lipoprotein.Model A, whole cohort; model B, subgroup of patients with Mediterranean diet score.
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AF patients restarting treatment with warfarin after gastric
ulcer bleeding. In the subgroup of 458 patients treated with
warfarin, the rate of MACE was 5.4% per year.27 Our results
are also in keeping with a prespecified analysis from the
ROCKET-AF trial, which showed that AF patients with prior
cardiac events are at higher risk of MACE than cardiovascular-
free patients.29
The novel finding of the present study is that patients
experiencing MACE disclosed significantly higher values of
LPS, as compared with patients free from events during
follow-up. In particular, we found that patients in the third
tertile of LPS (>100 pg/mL), as compared with the first one,
had the highest risk of MACE.
Our findings provide support and extend current knowl-
edge on the role of gut microbiota and its products in
many cardiovascular diseases, suggesting that they may not
only have an important pathogenetic role in human
atherosclerosis but may also have an important prognostic
value.
To explore potential mechanisms underlying the associa-
tion between LPS and MACE, we measured the urinary
excretion of 11-dehydro-TxB2, which is a validated marker of
platelet activation.30 We previously had demonstrated that in
AF platelet function is increased and significantly associated
with MACE incidence.25 A step forward in the knowledge of
platelet function in AF is provided by the present study,
suggesting that LPS may represent an important trigger for
platelet activation; consistent with this hypothesis is the
significant correlation between LPS levels and 11-dehydro-
TxB2 excretion. Previous in vitro study also demonstrated that
LPS amplifies platelet response to common agonists in a
range of concentration similar to that detected in our AF
population.31
However, other mechanisms may account for the
association between LPS and MACE. Thus, animal models
showed that long-term exposure to LPS was associated
with endothelial dysfunction32 and atherosclerotic plaque
destabilization,13 and in vitro LPS stimulation was associ-
ated with increased monocyte-derived thrombin genera-
tion.33
Although there was no association between circulating LPS
and classic cardiovascular risk factors, we found a significant
inverse association between adherence to Med-diet and LPS.
Med-diet represents a healthy dietary model recognized
worldwide for its favorable effect in the primary and
secondary prevention of cardiovascular events.34 In the
context of AF, we previously demonstrated that adherence
to Med-diet had several beneficial effects, including a
reduction of systemic oxidative stress26 and platelet activa-
tion,35 which were in turn associated with a lower rate of
Table 5. Circulating LPS Levels According to Single Foods
Foods Intake Median LPS P Value
1. Olive oil (≥1 tablespoon/d) Yes 50.0 (15.0-101.0) 0.273
No 58.0 (22.0-112.0)
2. Fruit (≥1 serving/d) Yes 48.0 (15.0-100.0) 0.009
No 73.0 (26.0-120.6)
3. Vegetables or salad
(≥1 serving/d)
Yes 49.0 (15.0-100.0) 0.195
No 56.0 (18.0-112.0)
4. Fruit (≥1 serving/d) and
vegetables or salad (≥1
serving/d)
Yes 48.0 (14.0-100.0) 0.164
No 55.0 (20.0-110.0)
5. Legumes (≥2 servings/w) Yes 45.0 (11.0-96.0) 0.005
No 56.0 (20.0-108.0)
6. Fish (≥3 servings/w) Yes 45.5 (12.0-105.0) 0.402
No 52.5 (17.0-105.0)
7. Wine (≥1 glass/d) Yes 49.0 (12.0-104.0) 0.186
No 51.0 (20.0-105.0)
8. Meat (<1 serving/d) Yes 50.0 (14.5-100.0) 0.085
No 56.0 (20.0-120.0)
9. Bread (both white bread
[<1/d] and rice
[<1/w])
or whole-grain bread
(>5/w)
Yes 48.5 (15.0-95.0) 0.382
No 53.0 (18.0-105.0)
LPS indicates lipopolysaccharide.
Table 4. Biochemical Characteristics of Atrial Fibrillation
Patients According to the Median Value of the Med-Diet
Adherence to
Med-Diet*
Mean
Value
Standard
Deviation P Value
Total cholesterol Low 178.3 36.3 0.902
High 177.9 40.9
HDL cholesterol Low 47.6 13.7 0.681
High 48.1 13.8
Triglycerides Low 117.3 54.7 0.922
High 117.7 51.9
LDL cholesterol Low 107.3 30.9 0.561
High 105.8 33.3
VLDL cholesterol Low 23.5 10.9 0.922
High 23.5 10.4
Log-LPS Low 3.9 1.0 <0.001
High 3.5 1.1
Log-thromboxane B2 Low 4.9 0.6 <0.001
High 4.5 0.8
HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; LPS,
lipopolysaccharide; VLDL, very low-density lipoprotein.
*Low adherence, 0-5 points of Med-diet; high adherence, 6-9 points of Med-diet.
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MACE. The novel finding of the present study is in the inverse
association between adherence to Med-diet and circulating
LPS, which provides a novel insight into the putative anti-
inflammatory effect exerted by Med-diet.31 It is interesting to
note that, among the Med-diet nutrients, fruits and legumes
were those showing a striking association with lower LPS,
indicating a relevant role for low-fat-content food in modulat-
ing circulating LPS.36
The study has clinical implications. The fact that LPS is an
independent predictor of MACE suggests that gut microbiota
may also favor cardiovascular disease in the setting of AF, but
the observational design of the study does not make it
possible to establish a cause-effect relationship. Indirect
evidence in support of this is provided by the inverse
association between Med-diet and circulating LPS. Only an ad-
hoc nutritional or pharmacologic interventional study aimed at
lowering LPS may clarify this issue. The inclusion of only white
patients and data collected by a single center are other
limitations of the study. Finally, we cannot exclude that LPS
may contribute to the increased MACE incidence through
other not yet identified mechanisms.
In conclusion, we provided further support to the role of
gut microbiota as a factor potentially implicated in cardiovas-
cular disease by demonstrating that circulating LPS is
associated with MACE in AF patients during a long-term
follow-up.
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None.
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